Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC PatientsCompleted
NCT07101874N/AUpdated Apr 17, 2026
Sponsor: AstraZeneca
Biliary Tract Cancer
Japan
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaRecruiting
NCT06942910Phase 2Updated Apr 17, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease With High Proteinuria
Russia
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompleted
NCT05166889Phase 3Updated Apr 16, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Belgium, Bulgaria, Canada +16 more
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of NirsevimabCompleted
NCT06042049Phase 3Updated Apr 16, 2026
Sponsor: AstraZeneca
Respiratory Syncytial Virus Infections
Japan
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.Completed
NCT05158387Phase 3Updated Apr 16, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Australia, Brazil, Chile, China +15 more
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.Completed
NCT05440656N/AUpdated Apr 15, 2026
Sponsor: AstraZeneca
Severe Eosinophilic Asthma
Greece
Selumetinib and Olaparib in Solid TumorsActive Not Recruiting
NCT03162627Phase 1Updated Apr 15, 2026
Sponsor: M.D. Anderson Cancer Center
Malignant Neoplasm of Breast · Malignant Neoplasms of Digestive Organs · Malignant Neoplasms of Female Genital Organs · Malignant Neoplasms of Male Genital Organs
United States
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)Completed
NCT03446547Phase 2Updated Apr 14, 2026
Sponsor: Vastra Gotaland Region
NSCLC, Stage I
Finland, Norway, Sweden
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.Completed
NCT06432764Phase 1Updated Apr 14, 2026
Sponsor: AstraZeneca
Crohn Disease
Sweden
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent GlioblastomaCompleted
NCT02866747Phase 1, Phase 2Updated Apr 14, 2026
Sponsor: Institut Claudius Regaud
Glioblastoma
France
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompleted
NCT05826366N/AUpdated Apr 14, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
Japan
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruiting
NCT04686305Phase 1Updated Apr 13, 2026
Sponsor: AstraZeneca
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
United States, Australia, Belgium, Brazil, Canada +14 more
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without FoodCompleted
NCT07404137Phase 1Updated Apr 13, 2026
Sponsor: AstraZeneca
Healthy Participants
United States
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerCompleted
NCT03462342Phase 2Updated Apr 13, 2026
Sponsor: University of Pennsylvania
High Grade Serous Carcinoma
United States
variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia PathwayNot Yet Recruiting
NCT07463976N/AUpdated Apr 13, 2026
Sponsor: The Royal Wolverhampton Hospitals NHS Trust
Chronic Lymphocytic Leukemia · Haematological Malignancy
United Kingdom
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompleted
NCT06973161N/AUpdated Apr 8, 2026
Sponsor: AstraZeneca
Bladder Cancer · Biliary Tract Cancer · Cervical Cancer · Endometrial Cancer
United States, Austria, Belgium, Canada, Czechia +7 more
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder CancerRecruiting
NCT06503614Phase 2Updated Apr 8, 2026
Sponsor: John Sfakianos
Non-muscle Invasive Bladder Cancer · Non-Muscle Invasive Bladder Urothelial Carcinoma
United States
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyRecruiting
NCT07295821Phase 2Updated Apr 8, 2026
Sponsor: AstraZeneca
Lung Cancer
China
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy ParticipantsCompleted
NCT06693765Phase 1Updated Apr 7, 2026
Sponsor: AstraZeneca
Renal Impairment · End-stage Kidney Disease · Healthy Participants
Bulgaria, Romania
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)Recruiting
NCT02819882N/AUpdated Apr 7, 2026
Sponsor: Spanish Breast Cancer Research Group
Breast Neoplasms
Spain
A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCERNot Yet Recruiting
NCT07515950N/AUpdated Apr 7, 2026
Sponsor: MedSIR
Biliary Tract Cancer (BTC)
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompleted
NCT02087423Phase 2Updated Apr 6, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Austria, Belgium, Canada, Czechia +13 more
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian CancerWithdrawn
NCT07060365Phase 1, Phase 2Updated Apr 3, 2026
Sponsor: AstraZeneca
Advanced/Recurrent Ovarian Cancer
Spain
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseCompleted
NCT06132841Phase 1Updated Apr 3, 2026
Sponsor: AstraZeneca
Healthy Participants
United States, Japan
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+PertuzumabTerminated
NCT05744375Phase 2Updated Apr 2, 2026
Sponsor: Spanish Breast Cancer Research Group
Locally Advanced Breast Cancer · Metastatic Breast Cancer
Spain

Previous page Next page